Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Has HbA1c \>7.0% and \<=10.5%~* Has a body mass index (BMI) \>=25 kg/m2 and \<=45 kg/m2~* Has received insulin glargine for 3 months prior to study start and has been on a stable dose for 1 month prior to study start~* If taking oral antidiabetic agents, has been on a stable dose for at least 2 months~Exclusion Criteria:~* Has been previously treated with Symlin/pramlintide (or has participated in a Symlin/pramlintide clinical study)~* Has received any investigational drug within 1 month of screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Pramlintide (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).